National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 42 of 66
Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00112684
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
NCT00262821
Pilots of Self-Collection for HPV DNA Detection
NCT00342511
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
NCT00182767
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00305656
Vorinostat in Treating Patients With Acute Myeloid Leukemia
NCT00305773
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
NCT00278330
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
NCT00273910
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT00303953
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NCT00310089
Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT00079040
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men
NCT00287833
Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer
NCT00290758
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
NCT00126659
Oxaliplatin and Topotecan in Advance Ovarian Cancer
NCT00313612
ZD6474 to Treat Advanced Brain Cancer in Patients
NCT00272350
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
NCT00086567
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
NCT00303797
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
NCT00255762
Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function
NCT00275093
Bevacizumab for Recurrent Malignant Glioma
NCT00271609
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
NCT00134043
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
NCT00301938
Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00290810
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
NCT00227591
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
NCT00309946
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT00238394
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
NCT00301769
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
NCT00112723
Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00243100
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
NCT00301847
Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus
NCT00233935
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
NCT00245024
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
NCT00243074
Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00310024
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
NCT00303836
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
NCT00303966
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
NCT00131937
Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung
NCT00301730
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
NCT00107536
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
NCT00119262
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
NCT00244972
Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
NCT00278382
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00275028
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
NCT00253370
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
NCT00132067
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
NCT00262834
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
NCT00288041
Vorinostat in Treating Patients With Kidney Cancer
NCT00278395
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
NCT00238212
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.